Bone marrow-derived multipotent mesenchymal stromal cells from horses after euthanasia by Schröck, Carmen et al.
Bone marrow-derived multipotent mesenchymal
stromal cells from horses after euthanasia
Carmen Schr€ock* , Carina Eydt†, Florian Geburek‡, Lena Kaiser*, Felicitas P€abst§,¶,
Janina Burk§,¶, Christiane Pfarrer† and Carsten Staszyk*
*Institute for Veterinary Anatomy, -Histology and -Embryology, Justus-Liebig-University, Giessen, Germany, †Institute of Anatomy, University of Veterinary
Medicine Hannover, Hannover, Germany, ‡Clinic for Horses, Justus-Liebig-University, Giessen, Germany, §Translational Centre for Regenerative Medicine
(TRM), University of Leipzig, Leipzig, Germany and ¶Faculty of Veterinary Medicine, Large Animal Clinic for Surgery, University of Leipzig, Leipzig,
Germany
Abstract
Allogeneic equine multipotent mesenchymal stromal cells (eMSCs) have been proposed for use in regenerative
therapies in veterinary medicine. A source of allogeneic eMSCs might be the bone marrow from euthanized
horses. The purpose of this study was to compare in vitro characteristics of equine bone marrow derived eMSC
(eBM-MSCs) from euthanized horses (eut-MSCs) and from narcotized horses (nar-MSCs). Eut-MSCs and nar-
MSCs showed typical eMSC marker profiles (positive: CD44, CD90; negative: CD11a/CD18 and MHCII) and
possessed tri-lineage differentiation characteristics. Although CD105 and MHCI expression varied, no differ-
ences were detected between eut-MSCs and nar-MSCs. Proliferation characteristics did not differ between eut-
MSCs and nar-MSCs, but age dependent decrease in proliferation and increase in MHCI expression was
detected. These results suggest the possible use of eut-MSCs for therapeutic applications and production of
commercial available eBM-MSC products.
Keywords: equine stem cells, flow cytometry, horse, proliferation assay, regenerative therapy.
Correspondence: Carsten Staszyk, Institute for Veterinary Anatomy, -Histology and -Embryology, Justus-Liebig-University,
Giessen, Germany.
E-mail: carsten.staszyk@vetmed.uni-giessen.de
Introduction
Equine bone marrow-derived multipotent mesenchy-
mal stromal cells, obtained from live horses, are the
focus of multiple experimental and clinical studies
evaluating their characteristics with regard to their
use in regenerative therapies (Arnhold et al. 2007;
Brehm 2008; Cortes et al. 2013; Renzi et al. 2013;
Smith et al. 2013). As far as the authors are aware,
however, there have been no experimental studies
reported which use eBM-MSCs obtained from eutha-
nized horses. It is widely accepted that multipotent
mesenchymal stromal cells (MSCs) selected for ther-
apeutic use express MSC-typical cell surface markers
such as CD44, CD90 and CD105, and provide exten-
sive proliferative capacity in vitro (Iacono et al.
2012b; Spaas et al. 2013). For most therapeutic
approaches autologous sternal bone marrow is har-
vested in order to isolate and expand eBM-MSCs.
Although the application of autologous MSCs avoids
the risk of immunorejection of the applied cells,
there are several problems associated with obtaining
autologous eBM-MSCs. First, the MSCs may be
altered by disease status and treatment with pharma-
ceutical products. Second, the harvesting procedure
bears the risk of thoracic and cardiac punctures
(Jacobs et al. 1983; Durando et al. 2006). Third, the
production of an injectable autologous eBM-MSC
product is a time consuming procedure that takes up
to five weeks (Brems & Jebe 2008). These disadvan-
tages might be avoided by the use of allogeneic
MSC-products obtained from euthanized or slaugh-
tered horses. Thus, the alternative use of allogeneic
MSCs has been proposed for regenerative therapies
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in people (Alison & Caplan 2009; Heng et al. 2009)
as well as in horses (Watts et al. 2011; Iacono et al.
2012a; Lange-Consiglio et al. 2013). The experimen-
tal use of allogeneic equine MSCs for treatment of
tendon lesions and other orthopaedic disorders has
delivered promising results without significant
adverse effects (Carrade & Borjesson 2013; Lange-
Consiglio et al. 2013). For the in vitro experiments,
the use of MSCs from euthanized horses would fol-
low the concept of replacement, reduction and
refinement in animal experiments. The aim of this
study was to compare in vitro characteristics of eBM-
MSCs obtained from euthanized and live horses par-
ticularly focussing on immunophenotype. According
to the suggestion of the ISCT (International Society
for Cellular Therapy) for the immunophenotyping of
human mesenchymal stromal cells, a panel of posi-
tive (CD44, CD90, CD105, MHCI) and negative
(CD11a/CD18, MHCII) commercially available stem
cell markers was assessed which had previously been
shown to cross react with equine cells. (Dominici
et al. 2006; Burk et al. 2013). Instead of a commonly
used doubling time assay, which takes an exponential
growing of the cell population for granted, a newly
designed proliferation assay was used to describe the
proliferation curve, based on the logistical function
that includes lag-, log-, and stationary phase. Addi-
tionally, the new proliferation assay enables discrimi-
nation between fast-proliferating and slow-
proliferating subpopulations within a given cell
population, possibly leading to a selection of fast
proliferating cells in the future.
Methods
Animals
Animal subjects included in this study were 9 warm-
blood horses, owned by the Equine Clinic of the
University of Veterinary Medicine Hannover, which
were first narcotized and later euthanized at the
Equine Clinic of the University of Veterinary Medi-
cine Hannover for reasons unrelated to this study.
The horses were divided into two groups: In five
horses bone marrow aspirates were gained before
euthanasia, in five horses bone marrow aspirates
were gained after euthanasia; one horse belonged to
both groups.
Horses that had undergone previous bone marrow
(BM) aspiration were excluded from this study. Par-
ticular attention was paid to collect BM from donors
from a wide range in age.
Isolation and expansion of BM-MSCs from live
horses
Bone marrow was aspirated from the sterna of five
horses under general anesthesia (No. 2, 4, 6, 8, 9b
according to Table 1) using a 13 G bone marrow
biopsy needle (Angiotech, Wyomissing, USA).
Horses were sedated with xylazine (Xylazin 2%,
CP-Pharma GmbH, Burgdorf, Germany) and gen-
eral anesthesia was induced by ketamine (Narketan
100 mg/mL, Vetoquinol GmbH, Ravensburg, Ger-
many) and midazolam (Midazolam 5 mg/mL, B.
Table 1. Data of bone marrow donors.
Horse Bone marrow
aspirate
Euthanized/
narcotized
Sex Breed Age Disease
1 1 Eut Gelding Warmblood 28 years Colic
2 2 Nar Gelding Warmblood 28 years Infirmity
3 3 Eut Mare Haflinger 23 years Colic
4 4 Nar Mare Warmblood 22 years Lameness
5 5 Eut Gelding Warmblood 12 years Colic
6 6 Nar Mare Warmblood 16 years Lameness
7 7 Eut Gelding Haflinger 7 years Lameness
8 8 Nar Mare Warmblood 3 years Unknown
9a 9 Eut Mare Warmblood 2 weeks premature Sepsis
9b 10 Nar Mare Warmblood 2 weeks premature Sepsis
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Braun Melsungen AG, Melsungen, Germany) using
standard drug dosages. The horses were placed in
dorsal recumbency and general anesthesia was main-
tained by isoflurane (Isofluran CP, CP-Pharma
GmbH, Burgdorf, Germany) in clean oxygen.
Horse No. 9a/b (Table 1) was sedated and narco-
tized as later described for euthanized horses. One
sample of bone marrow was harvested under general
anesthesia (BM aspirate No. 9, Table 1) and then a
second one within 30 min after euthanasia (BM aspi-
rate No. 10, Table 1).
Five millilitre bone marrow aspirates were
obtained from sternebra 4 or 5 using ultrasound guid-
ance according to Eydt et al. (2014) and carried to
the lab within 15 min inside a styrofoam container.
The bone marrow samples were centrifuged at 103
rcf for 15 min and the generated cell pellets resus-
pended in 10 mL proliferation medium (pmol/L,
Mensing et al. 2011). The suspension was filtered
through a 70 lm filter and was carefully layered over
14 ml Easycoll (1.086 g/mL, Biochrom AG, Berlin,
Germany). After density gradient centrifugation at
400 rcf for 35 min (without brake) the mononuclear
cell population (MNCs) was aspirated and cells were
washed two times in PBS (DPBS 1x, Life Technolo-
gies GmbH, Darmstadt, Germany). All cells
harvested from 5 mL BM were seeded as passage 0
into two 25 cm² cell culture flasks, containing
5 mL pmol/L. Medium was changed 4–24 h after
seeding, and subsequently every 2–3 days. When 70–
80% confluence was reached, after 7–22 days, cells
were detached using trypsin (0.05% Trypsin-EDTA,
Life Technologies GmbH, Darmstadt, Germany)
and half of the cells were cryopreserved for later use,
the other half was passaged. In the first passage, cells
from each aspirate were seeded in two 75 cm² cell
culture flasks (1 9 105 to 3 9 105 cells) containing
13 mL pmol/L and medium was changed every
2–3 days until 70–80% confluence was reached and
cells were further passaged or cryopreserved. The
same procedure was repeated in the passage 2 and 3.
Cells in passage 1, 2 or 3 reached confluence after
6–15 days. Approximately 4 9 106 cells were har-
vested from two 75 cm² flasks and used for flow
cytometry analysis. Flow cytometry and proliferation
assays were performed with cells from passages 1–3.
Isolation and expansion of BM-MSCs from
euthanized horses
Five horses (No. 1, 3, 5, 7, 9a, Table 1) were eutha-
nized for reasons unrelated to this study. The horses
were sedated with xylazine (Proxylaz, Bela-Pharm
GmbH & Co. KG, Vechta, Germany) and narcotized
using ketamine (Ketamin, 10%, Bela-Pharm
GmbH & Co. KG, Vechta, Germany) and diazepam
(Diazepam 10 mg, Rotexmedica, Trittau, Ger-
many). Subsequently, these horses received T61
(Intervet, Unterschleißheim, Germany) for euthana-
sia. Standard drug dosages were used for all drugs.
Within 30 min after euthanasia, 2 9 5 mL BM were
aspirated and processed as described for the live
horses.
Flow cytometry analysis for immunophenotyping
Two positive markers (CD90 and CD105) and one
negative marker (MHCII) were selected according
to the recommendation of the ISCT for identifying
human MSCs [19]. Additionally, the presence of
CD44, MHCI (positive markers) and absence of
CD11a/CD18 (negative marker) was determined.
Cells were incubated with 10% horse serum
(donor horse serum, heat inactivated, PAA Labo-
ratories GmbH, Pasching, Austria) in PBS for
15 min at room temperature and washed using
washing buffer (WB) containing 98.5% PBS, 1%
BSA (PAA Laboratories GmbH, Pasching, Aus-
tria), 0.01% NaN3 (Merck-Schuchardt, Hohen-
brunn, Germany) and 0.5% goat serum (Institute
for Veterinary Anatomy, Histology and Embryol-
ogy, Giessen, Germany) to block non-specific anti-
body binding. Subsequently, cells were pelleted in
aliquots containing 2 9 105 cells on a 96-well plate
with V-bottom and incubated with primary anti-
bodies (Table 2). Cells were then washed twice
with WB and stained with appropriate secondary
antibodies (Table 2). Then, cells were washed
twice, resuspended in PBS and at least 1 9 105
vital cells were analysed by flow cytometry (Accuri
C6, BD Bisoscience, Heidelberg, Germany) using
Accuri C6 software (BD Bisoscience, Heidelberg,
Germany). Unlabelled cells, secondary antibody
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only labelled cells and isotype controls were used
as control samples. Two different secondary anti-
bodies without spectral overlap were used for mul-
ticolour analyses (Table 2). For negative markers
(MHCII, CD11a/CD18) positive controls were per-
formed on eBM derived MNCs, which include
hematopoietic stem cells (data not shown).
Gating strategy
Dead cells were marked and excluded from the anal-
ysed gate, using the viability dye 7-AAD (BD Biso-
science, Heidelberg, Germany) in accordance with
the manufacturers0 instruction.
Modified Proliferation assay
The proliferation dye eFluor 670 (eBioscience,
Frankfurt, Germany) is equally distributed to daugh-
ter cells during mitosis. The manufacturer’s staining
protocol for suspension cells was adapted to the spe-
cial needs of adherent equine MSCs.
To synchronize the cell cycle, 3.5 9 106 eBM-
MSCs, suspended in DMEM (DMEM 1x, 4.5 g/L
D-Glucose, Life Technologies GmbH, Darmstadt,
Germany), were placed on a soft shaker at 8°C.
After 12 h, cells were washed twice with pre-
warmed (37°C) PBS and were resuspended in
1.0 ml PBS. Afterwards, cell suspensions were
divided into 2 9 0.5 mL. One portion was thor-
oughly mixed with 0.5 mL eFluor 670 (1:200). The
other portion (control) was mixed with 0.5 mL
PBS. Both portions were incubated for 10 min at
37°C in the dark. Staining was stopped by adding
2.5 mL cold pmol/L and by incubation on ice for
5 min (in the dark). Subsequently, the cells were
washed three times with pmol/L. Cells were
counted by flow cytometry and seeded on 6-well
plate at a density of 1 9 10³ cells/cm². During a
period of 10 days, cells were collected successively
at six time points (including lag-, log- and station-
ary-phase) and were analysed by flow cytometry.
Obtained data were analysed by logistic regression
using the statistical software program BMDP6D
(BMDP/Dynamic, Release 8.1 [Dixon, 1993]). The
following parameters were determined and used
for comparison among the different donors (Fig. 1):
1. G: boundary value, the maximum cell number
attainable from 9.6 cm² culture dish
2. G1: time to reach the half boundary value
3. G2: maximal proliferation speed of the cell
population
4. G3: time to reach 1.5 9 105 cells
5. G4: cell number after 150 h of cultivation time
Fig. 1. Example of a proliferation curve of eBM-MSCs. Logistical regression displaying the boundary value, the maximum cell number attainable
from 9.6 cm² culture dish (G), the time to reach half boundary value (G1), the maximal proliferation speed of the cell population (G2), the time
to reach 1.5 9 105 cells (G3) and the cell number after 150 h of cultivation time (G4).
© 2017 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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The calculated values (G–G4) were statistically
analysed using a paired-sample t-test (eut- and nar-
MSCs from similarly aged donors were paired), a
covariance analysis and correlation diagrams, in
order to analyse differences between the assigned
groups of MSCs from narcotized horses and MSCs
from euthanized horses and to determine the impact
of the donor age. A p-value below 0.05 was regarded
as statistically significant.
After 3 days the number of cell divisions under-
gone by each cell was calculated by measuring the
decrease in fluorescence intensity in relation to the
initial fluorescence intensity. This information was
used to determine the number of cells from different
cell generations within a population. The assessment
of the generation number was limited to the 6th cell
generation as the fluorescence intensity of eFluor
670 decreases after that time. All experiments were
performed in triplicate.
Differentiation assays
To confirm tri-lineage differentiation capacity
according to the ISCT (Dominici et al. 2006), osteo-
genic, chondrogenic and adipogenic differentiation
assays were performed using MSCs obtained from
the oldest and the youngest horses as examples of
the assigned groups (No. 1, 2, 9a and 9b; Table 1).
Osteogenic differentiation/chondrogenic
differentiation
3 9 105 cells were placed into a 15 mL tube within
0.5 mL medium for osteogenic or chondrogenic dif-
ferentiation and centrifuged for 1 min with 100 rcf.
Pellets were cultured under standard conditions, 5%
CO2 at 37°C. Negative controls were supplied with
pmol/L instead of differentiation media. Medium was
changed every 2–3 days. At day 14, the pellets were
fixed in 10% buffered formalin, and processed rou-
tinely for histology. Osteogenic differentiation was
demonstrated by Von-Kossa staining showing miner-
alization (Arnhold et al. 2007; Cortes et al. 2013).
Chondrogenic differentiation was demonstrated by
Alcian blue staining showing acidic polysaccharides
(Colleoni et al. 2009; Cortes et al. 2013).
Adipogenic differentiation
2 9 104 cells/cm² were seeded on a 24-well plate sup-
plied with 0.5 mL pmol/L. Medium was changed
every 2–3 days until 70% confluence. Afterwards,
adipogenic differentiation medium was added. Nega-
tive controls were formed by supplying pmol/L
instead of the differentiation medium. At day 14, the
presence of fat droplets was demonstrated using Oil
red O staining.
Results
Viable, plastic adherent and proliferating cells were
obtained from all 10 bone marrow aspirates.
Immunophenotypic characterisation
All eBM-MSCs from narcotized horses and from
euthanized horses presented high percentages (>90%)
of CD44 and CD90 positive cells (Figs. 2, 3). The per-
centages of other positive markers of MSCs (MHCI,
CD105) varied widely between MSC populations.
MHCI was present in 91.4%  7.1 of eut-MSCs and
in 76.7%  19.1 of nar-MSCs respectively. CD105
was expressed in 33.9%  27.2 of eut-MSCs and in
45.7%  20.9 of nar-MSCs respectively. None of the
detected differences were statistically significant.
The expression of the MSC negative marker
(CD11a/CD18) and of MHCII was consistently low
(<2.2%) in all nar-MSCs and eut-MSCs.
A covariance analysis showed a significant
correlation (P = 0.016) between the age of the donor
horse and the expression of MHCI. The percentage
of MHCI expressing cells increased per year of age
by 1%.
Proliferation characteristics
According to the calculated cell divisions, cells were
assigned to 4 proliferation types (Figure 4):
1. Type I: Slow-proliferating cells (generation 1 and
2)
2. Type II: Moderate-proliferating cells (generations
3–5)
© 2017 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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Fig. 2. Flow cytometry analysis. Histograms display fluorescence intensity on x-axis and cell counts on y-axis. Nar-eBM-MSC and eut-eBM-MSC
highly expressed CD44 and CD90. CD105 and MHC I expression varied in wide ranges. CD11a/CD18 and MHCII were expressed by very few
cells. Left peaks represent isotype control stainings, right peaks represent antibody staining with corresponding percentage of positive cells
(percentages shown as mean of measured doublets).
© 2017 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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3. Type III: Fast-proliferating cells (generations >5)
4. Type IV: Non-proliferating cells (generation 0)
From 30 cell cultures (triplets from each culture
obtained, that is, 15 nar-MSCs, 15 eut-MSCs), 23 (12
nar-MSC and 11 eut-MSC cultures) contained a
heterogeneous mixture of all defined proliferation
types, and the remaining 3 nar-MSC and 4 eut-MSC
cultures contained no fast-proliferating cells. In 10
nar-MSCs and 11 eut-MSCs, the majority of cells
were assigned to the moderate proliferating cell type.
In 5 nar-MSCs and in 4 eut-MSCs the majority of
cells were slow-proliferating cells. All eut-MSCs
contained less than 2.1% fast-proliferating cells. All
nar-MSCs (except horse No. 4) contained more than
2.4% fast-proliferating cells (Figure 4).
Correlation diagrams demonstrated that the maxi-
mum proliferation speed (i.e. parameter G2)
decreased with increasing age of the donor. No sta-
tistically significant differences between nar-MSCs
and eut-MSCs were detected.
Tri-lineage differentiation
All investigated cells showed their tri-lineage differ-
entiation potential and differentiated into
Fig. 3. Marker expression of eBM-MSCs. Box plots of the distribution of percentages of eBM-MSCs from euthanized and narcotized horses,
which are positive for the marker expressions. Boxes represent the lower and upper quartiles, lines inside the boxes are medians, whiskers rep-
resent minimum and maximum values and circles represent mean values. Eut-MSCs and nar-MSCs show no significant differences (P > 0.05).
Fig. 4. Proliferation speed of eBM-MSCs. Percentage of slow- (Type I, red), moderate- (Type II, green), fast- (Type III, purple) and non- (Type
IV, blue) proliferating cells in expanded cultures from bone marrow aspirates 1–10. Means of triplets displayed.
© 2017 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
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adipogenic, chondrogenic and osteogenic directions
(Fig. 5). All controls did not differentiate.
Discussion
The potential use of allogeneic equine MSCs for
regenerative therapies could help to overcome disad-
vantages associated with the harvest of autologous
bone marrow. The references show, that autologous
bone marrow is usually taken from sedated horses
(Brems & Jebe 2008; Bourzac et al. 2010), however,
there are previous studies, that obtained BM-MSCs
also from narcotized horses (Frisbie et al. 2009).
Although the risks of this method are minimal
(Kasashima et al. 2011; Eydt et al. 2014), the horses
are exposed to stress and pain. Another disadvantage
is the long post-harvesting time required to produce
an injectable autologous cell product (Brems & Jebe
2008). The disadvantages of the autologous sampling
method could possibly be avoided if MSCs from one
Fig. 5. Results of tri-lineage differentiation assays of eBM-MSCs. Von Kossa staining following osteogenic differentiation (a) and corresponding
negative control (b). Alcian blue staining following chondrogenic differentiation (c) and corresponding negative control (d). Oil red O staining fol-
lowing adipogenic differentiation (e) and corresponding negative control (f). Scale bar = 50 lm.
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healthy horse, cryopreserved in many samples, could
be used for therapy in many patients. Additionally
using MSCs from euthanized horses may increase
their availability for research.
Recently, bovine BM-MSCs were successfully har-
vested from abattoir-derived bovine fetuses (Cortes
et al. 2013). Vital, proliferating cells, expressing a
typical set of MSC markers were obtained and multi-
lineage differentiation was demonstrated. As shown
in our data, vital and proliferating cells are also
obtainable from euthanized horses. Mesenchymal
stromal cells harvest and expansion was successful
for at least 30 min after euthanasia, however, the
maximum time frame for successful MSC harvest
from dead animals remains to be determined, as nei-
ther our study nor the study presented by Cortes
et al. (2013) were designed to investigate this intrigu-
ing parameter. In our preliminary experiments, vital
eBM-MSCs were successfully obtained even five
hours after euthanasia (data not shown).
Unfortunately it was not possible to gain paired
samples from each horse before and after euthanasia,
as was done for horse No. 9. Therefore, we tried to
get samples from horses in a wide range of age in
both groups to get an overview about the characteris-
tics of the cells from horses of different ages.
Previous studies suggested the use of fetal abat-
toir-derived bovine BM-MSCs for regenerative ther-
apies because the cells show typical characteristics of
bovine MSCs from live animals (Cortes et al. 2013).
However, there is no information about possible dif-
ferences between MSCs obtained from abattoir-
derived fetuses and those from live animals.
Although the harvest of BM-MSCs from eutha-
nized horses provides a new opportunity to collect
large quantities of cells, potential differences between
BM-MSCs obtained from euthanized horses and live
horses might restrict the speculative application.
Therefore, we performed a comparative evaluation of
BM-MSC characteristics that were recognized as cru-
cial parameters for the potential use of MSCs in
regenerative therapies. Special attention was paid to
use a reliable panel of equine MSC markers to investi-
gate selected criteria relevant for allogeneic applica-
tions and to provide detailed information about the
particular proliferation capacity of the cells.
Immunophenotyping
The MSC markers used in this study (positive mark-
ers CD44, CD90, MHCI, CD105, negative markers
CD11a/CD18, MHCII) were selected in accordance
with several studies characterizing equine MSC from
different sources (Burk et al. 2013). Although the
utilized antibodies for CD44 and CD90 were pro-
duced against non-equine species, they possess a high
level of cross reactivity and were previously recog-
nized as reliable markers for equine MSC (Arnhold
et al. 2007; Mensing et al. 2011; Burk et al. 2013). To
ensure reliable immunophenotyping, we used equine
specific antibodies against MHCI, CD11a/CD18 and
MHCII. As expected, the vast majority of plastic
adherent and expanding cell cultures highly
expressed CD44, CD90 and MHCI, but did not show
CD11a/CD18 and MHCII reactivity. Although the
cross reactivity of anti-human CD105 was confirmed
by the manufacturer, the expression of CD105 was
highly variable. Therefore, CD105 did not serve as a
reliable marker, as previously reported for equine
peripheral blood MSCs (Spaas et al. 2013).
According to the established marker panel, no sig-
nificant differences between nar-MSCs and eut-MSCs
were present. Thus, cells with the ability to express
typical stem cell markers are obtainable from eutha-
nized horses for at least 30 min after euthanasia. This
result supports a hypothesis that emphasizes the need
for a hypoxic environment in the stem cell niche. It
has been proposed that due to a hypoxic environment
prevents cellular processes that promote cell differenti-
ation and therefore conserve the undifferentiated sta-
tus of the stem cell (Ivanovic 2009). It is hypothesized
that lack of adverse reactions for allogeneic treatments
is due to the absence of MHCII and the immunosup-
pressive effect of MSCs in general (Heng et al. 2009;
Rafei et al. 2009; Roemeling- Rhijn et al. 2013; Li et al.
2014). Nevertheless, the range of different conditions
the horses had before nar- or eut-MSCs were har-
vested, did not affect the expression of the markers.
Proliferation capacity
An essential aspect for evaluating MSCs in vitro is
their capacity to proliferate (Dominici et al. 2006).
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Moreover, it is assumed that the in vitro proliferative
capacity is positively correlated with the regenerative
capacity of MSCs (Gilbert & Blau 2011). Most
assessments of the proliferative capacity are con-
ducted by calculating the cell doubling time (DT)
based on the number of seeded cells and the number
of cells after a defined time in the culture (Vidal
et al. 2007; Iacono et al. 2012b; Cortes et al. 2013).
This procedure provides valid results for a phase of
exponential cell proliferation. However, prolifera-
tion of cell populations in vitro is rather character-
ized by a non-exponential, s-shaped proliferation
curve. Thus, the mere doubling time provides only
limited information.
In order to detect cells displaying different prolif-
eration capacities within a cell population we con-
ducted a modified proliferation assay utilizing a
proliferation dye and flow cytometry. As previously
investigated, the data corresponded to the typical s-
shaped proliferation curve of expanding cells in vitro
and therefore allowed detailed analysis of prolifera-
tion characteristics. The identification of different
cell generations elucidated a heterogeneous mixture
of subpopulations with different proliferative capaci-
ties. This result was unexpected as other investigated
equine MSC cultures were characterized by very
homogeneous cell content (Arnhold et al. 2007).
However, homogeneity of MSCs in these reports was
determined according to their fibroblast-like mor-
phological characteristics. Furthermore, the applied
proliferation assays were not able to detect differ-
ences in proliferation characteristics among cells
within a single culture. Pre-selection of fast-prolifer-
ating cells could improve the quality of cell products
for research and therapy. However, the data
obtained here do not provide cellular markers suit-
able for the predictive selection of those cells.
Although statistical analyses did not reveal any
proliferation differences between eut-MSCs and nar-
MSCs, there was a negative correlation between the
age of the donor horse and the maximum prolifera-
tion speed. This might be of importance for selecting
appropriate donors. Besides an accelerated in vitro
expansion speed, eBM-MSCs collected from younger
horses might possess advantageous regenerative
capacities. This assumption is based on studies that
demonstrated telomere shortening in human BM-
MSC with increasing donor age, limiting the regener-
ative capacity of these cells (Baxter et al. 2004).
Conclusion
To the best of the authors0 knowledge, the harvest of
vital and proliferative eBM-MSCs from euthanized
horses has not been previously described. In this
study, eBM-MSCs obtained from euthanized horses
and from live horses did not differ in terms of expres-
sion of MSC markers or proliferative capacities. We
suggest that eut-MSCs are suitable at least for scien-
tific studies based on in vitro techniques. This would
meet the obligation for replacement, reduction and
refinement in animal experiments. Moreover, the
results obtained here suggest a potential for use of
eut-MSC as commercially available products in allo-
geneic MSC therapies. This assumption has been
supported by several clinical studies that successfully
utilized allogeneic equine MSCs derived from fetal
tissues (Watts et al. 2011; Iacono et al. 2012a; Lange-
Consiglio et al. 2013) and from BM of adult donor
horses (Guest et al. 2008). Moreover, allogeneic
MSCs were already successfully applied in clinical
human studies (Alison & Caplan 2009; Chang et al.
2014; Guest et al. 2008).
This study is limited by the number of donor
horses and their individual differences in disease, age
and genetics. Although these differences might have
effects on the characteristics of the harvested MSCs,
no significant differences according to the used mar-
ker panel were detected. These results justify further
investigations to confirm the presented data and to
evaluate the possible negative effects of euthanasia
on the target cells, with special consideration for the
technique and chemicals used for that purpose. The
use of MSCs from slaughtered instead of euthanized
horses could be considered to avoid influences from
diseases or drugs on the obtained cells.
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